Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Search in posts
Search in pages
Filter by Categories
Abstracts
Case Report
Case Report, Infectious Diseases
Case Report, Nephrology
Case Series
Case Series, Nephrology
Commentary
Editorial Board
EDITORIAL BOARD 2026-2-2
Original Article, Urology and Renal Surgery
Original Research Article
Original Research Article, Endocrinology and Metabolism
Original Research Article, Nephrology
Perspectives and Opinions
Perspectives and Opinions, Health Education
Prespective
Review Article
Review Article, Dialysis and Transplantation
Review Article, Nephrology
Review Article, Pediatric Nephrology
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Search in posts
Search in pages
Filter by Categories
Abstracts
Case Report
Case Report, Infectious Diseases
Case Report, Nephrology
Case Series
Case Series, Nephrology
Commentary
Editorial Board
EDITORIAL BOARD 2026-2-2
Original Article, Urology and Renal Surgery
Original Research Article
Original Research Article, Endocrinology and Metabolism
Original Research Article, Nephrology
Perspectives and Opinions
Perspectives and Opinions, Health Education
Prespective
Review Article
Review Article, Dialysis and Transplantation
Review Article, Nephrology
Review Article, Pediatric Nephrology
View/Download PDF
Review Article
2 (
3
); 87-93
doi:
10.25259/WARM_19_2025

Translate:

Renal cell carcinoma: Molecular mechanisms and emerging therapeutic strategies

Author affiliations
Department of Pharmacology, Shree Aryatej Institute of Pharmacy, Morbi, Gujarat, India
Department of Pharmacy, Shree H.N. Shukla Institute of Pharmaceutical Education and Research, Rajkot, Gujarat, India
Article History
Corresponding author(s)
Author image
Corresponding author: Arunkumar Ramjibhai Vaghela, Department of Pharmacology, Shree Aryatej Institute of Pharmacy, Morbi, Gujarat, India. drxavaghela@gmail.com
Article tools · PDF & citations

Abstract

Renal cell carcinoma (RCC) poses a persistent clinical challenge, mainly due to its resistance to conventional therapies. With increased detection through modern imaging, more cases are being identified early, yet advanced or metastatic RCC remains challenging to treat. A deeper understanding of RCC’s molecular underpinnings has reshaped treatment strategies. Central to this is the von Hippel-Lindau (VHL) – hypoxia-inducible factor (HIF) – vascular endothelial growth factor pathway, which drives tumor angiogenesis, particularly in clear cell RCC. Disruption of this axis has been crucial in designing targeted therapies. In addition, pathways such as mammalian target of rapamycin and metformin (MET) play important roles in tumor growth and progression in certain subtypes. Immunotherapy has also redefined outcomes, especially with the success of immune checkpoint inhibitors, which help the body’s immune system recognize and fight cancer cells. Combining immunotherapy with targeted agents has become standard in many treatment settings due to their complementary effects. However, challenges remain – such as drug resistance and a lack of reliable biomarkers to guide therapy choices. Recently, HIF-2α inhibitors like belzutifan have emerged as promising precision treatments, especially in tumors with VHL mutations. As research continues, integrating molecular insights with clinical practice holds the potential to improve survival and quality of life for patients living with RCC.

Keywords

  • Immunotherapy
  • Mammalian target of rapamycin pathway
  • Molecular pathogenesis
  • Renal cell carcinoma
  • Vascular endothelial growth factor
Licence
This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License, which allows others to remix, transform, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

How to cite this article: Vaghela AR, Dulera M, Marakana D. Renal cell carcinoma: Molecular mechanisms and emerging therapeutic strategies. World Adv Renal Med. 2026;2:87-93. doi: 10.25259/WARM_19_2025

INTRODUCTION

Renal cell carcinoma (RCC), a malignant tumor originating from the renal tubular epithelium, represents a formidable challenge in oncology. Accounting for approximately 90% of all kidney cancers and constituting a notable 2–3% of all adult malignancies worldwide, its incidence has been steadily climbing in recent decades .[1] This rise is partly attributable to the widespread use of advanced imaging techniques, which frequently lead to the incidental detection of smaller, earlier-stage tumors. Despite improved early detection, a concerning one-third of patients still present with metastatic disease at diagnosis, a stage that was historically notoriously refractory to conventional cytotoxic chemotherapy and traditional radiation therapy.[1,2] This bleak prognosis underscored an urgent need for novel therapeutic paradigms.

The turning point in the management of metastatic RCC arrived with the seminal discovery of the pivotal role played by the von Hippel-Lindau (VHL) – hypoxia-inducible factor (HIF) axis, particularly in clear cell RCC (ccRCC), the most prevalent subtype. This profound molecular understanding paved the way for the rational design and development of targeted agents that specifically interfere with vascular endothelial growth factor (VEGF)-mediated angiogenesis, a hallmark of these tumors. More recently, the field has been further revolutionized by the advent of immune checkpoint inhibitors (ICIs), which have demonstrated remarkable efficacy by reactivating the patient’s intrinsic anti-tumor immune responses.[2,3] These breakthroughs have fundamentally reshaped the treatment landscape for RCC, offering unprecedented hope and durable responses for a subset of patients.

EPIDEMIOLOGY AND RISK FACTORS

The global distribution and incidence of RCC exhibit considerable variability, with higher rates generally observed in developed nations. While it can occur at any age, the disease typically manifests later in life, with its incidence peaking in the sixth to seventh decades. Gender plays a notable role, with men being diagnosed approximately twice as frequently as women.[4] This demographic disparity suggests underlying genetic, hormonal, or lifestyle influences that are not yet fully understood.

Several modifiable and non-modifiable factors have been consistently identified as increasing the risk of developing RCC. Among the most significant modifiable risks is smoking, which is a well-established causative agent, increasing the risk of RCC by approximately 50% for current smokers.[5,6] The cumulative exposure to carcinogens in tobacco smoke is thought to drive cellular changes. Similarly, obesity stands out as a significant independent risk factor, particularly for ccRCC, likely through mechanisms involving chronic inflammation, altered hormone profiles, and metabolic dysregulation. Hypertension is another common comorbidity that not only affects kidney function but also independently contributes to an elevated RCC risk. Furthermore, individuals with chronic kidney disease and those undergoing long-term dialysis are at an increased predisposition due to the development of acquired cystic kidney disease. Specific occupational exposures, such as to trichloroethylene, have also been implicated as contributing factors. While the majority of RCC cases are sporadic, a small but important proportion, approximately 4–5%, is linked to underlying hereditary syndromes. These include VHL disease, hereditary papillary RCC (pRCC) (associated with MET mutations), hereditary leiomyomatosis and RCC (FH-related), and Birt–Hogg–Dubé syndrome (folliculin (FLCN)-related), highlighting the role of germline genetic predispositions.[7]

HISTOLOGICAL SUBTYPES

RCC is not a singular entity but rather a heterogeneous collection of malignancies, each possessing distinct histological features, molecular signatures, and clinical behaviors. This heterogeneity profoundly impacts treatment decisions and prognosis. ccRCC remains the predominant subtype, accounting for a substantial 75–80% of all cases.[7] Under microscopic examination, ccRCC is characterized by cells with abundant, clear cytoplasm, a feature attributed to the accumulation of glycogen and lipids. This subtype is almost universally defined by the inactivation of the VHL tumor suppressor gene, either through mutation or epigenetic silencing. Clinically, ccRCC tends to be more aggressive and prone to metastasis compared to the non-clear cell subtypes.

The second most common variant is pRCC, comprising approximately 10–15% of RCC diagnoses.[8] This subtype is histologically identified by its distinctive papillary (finger-like) growth patterns. pRCC is further subdivided into Type 1, which is often multifocal and typically associated with activating mutations in the MET proto-oncogene, and Type 2, which generally exhibits a more aggressive clinical course and a heterogeneous molecular etiology.[9]

Chromophobe RCC (chRCC) constitutes a smaller proportion, around 5% of RCC cases.[10] Its cells are characterized by distinct cell membranes and pale, flocculent cytoplasm. While unique, chRCC generally carries a more favorable prognosis compared to ccRCC, presenting a less aggressive clinical picture. Other rare subtypes, such as collecting duct carcinoma and medullary RCC, account for only a minute fraction of kidney cancers but often pose significant therapeutic challenges due to their aggressive nature and the absence of specific targeted therapies.

MOLECULAR MECHANISMS IN RCC

The remarkable progress in RCC treatment is fundamentally rooted in a detailed understanding of the specific molecular alterations that drive its pathogenesis, enabling the transition from indiscriminate cytotoxic approaches to precision medicine.

VHL–HIF–VEGF pathway: The central axis in ccRCC

At the heart of ccRCC tumorigenesis lies the profound dysfunction of the VHL tumor suppressor gene, which is inactivated in approximately 70–90% of sporadic ccRCC cases through mutation, deletion, or epigenetic silencing.[11] In normal, oxygen-rich physiological conditions (normoxia), the VHL protein (pVHL) is a critical component of an E3 ubiquitin ligase complex. This complex’s primary function is to recognize and tag (HIF-1α and HIF-2α), which are key transcription factors, for rapid ubiquitination and subsequent degradation by the proteasome. This ensures that HIFs, which govern cellular responses to low oxygen, remain at low levels when oxygen is plentiful.

However, in ccRCC, the inactivation of VHL abrogates pVHL’s ability to bind and degrade HIF-α subunits. This leads to the pathological, constitutive stabilization and accumulation of HIF-1α and, more prominently, HIF-2α, even under normal oxygen conditions.[12] The persistent high levels of HIFs then aberrantly activate the transcription of numerous target genes that are typically only expressed during true hypoxia. These genes orchestrate a cascade of biological processes crucial for tumor growth and progression:[13,14]

  • VEGF: A potent pro-angiogenic factor, leading to the characteristic hypervascularity observed in ccRCC tumors, ensuring a blood supply for rapid growth.[15]

  • Platelet-derived growth factor (PDGF): Another key player in cell proliferation, migration, and angiogenesis.

  • Glucose transporter 1 and glycolytic enzymes: These promote aerobic glycolysis (the “Warburg effect”), enabling cancer cells to rapidly produce adenosine triphosphate even in the presence of oxygen, a metabolic shift that supports their accelerated growth.[16]

  • Transforming growth factor-alpha: A growth factor that stimulates cell proliferation.

  • Erythropoietin: Overexpression can lead to paraneoplastic syndromes, such as erythrocytosis.

Thus, the VHL-HIF pathway’s dysregulation creates a perpetual “hypoxic mimicry” state within the tumor, driving its aggressive phenotype.

Mammalian target of rapamycin (mTOR) pathway dysregulation

The mTOR pathway is a pivotal intracellular signaling cascade that acts as a central hub, integrating various extracellular and intracellular cues (such as growth factors, nutrient availability, and energy status) to regulate fundamental cellular processes, including cell growth, proliferation, metabolism, and angiogenesis.[17] The mTOR complex 1 (mTORC1) is particularly implicated in RCC.

In RCC, especially ccRCC, dysregulation of the mTOR pathway can occur through various mechanisms. While less common than VHL alterations, mutations in tumor suppressor genes like tuberous sclerosis complex (TSC)1/TSC2 (as seen in TSC, a hereditary RCC syndrome) or loss of phosphatase and tensin homolog can directly lead to constitutive activation of the mTOR pathway. Furthermore, the downstream effects of aberrant VHL-HIF signaling can indirectly enhance mTORC1 activity and, consequently, further stimulate HIF-1α synthesis and VEGF expression. Given its central role in cell biology and its influence on processes critical for tumor growth, the mTOR pathway represents a significant and actionable therapeutic target in RCC, leading to the development of specific inhibitors.[18,19]

MET Pathway in pRCC

While VHL is the dominant player in ccRCC, other molecular pathways are critical in different RCC subtypes. In Type 1 pRCC, activating mutations or gene amplifications in the MET proto-oncogene are frequently observed.[18] MET encodes for a receptor tyrosine kinase (RTK) that, when activated by its ligand hepatocyte growth factor (HGF), triggers downstream signaling cascades involved in cell proliferation, survival, migration, and invasiveness. The constitutive activation of MET in pRCC drives unchecked cellular growth and contributes to the invasive potential of these tumors. This understanding has led to the exploration of MET inhibitors in this specific subtype.[20,21]

Immune evasion mechanisms

Interestingly, despite the pro-angiogenic and proliferative nature of RCC, it is also considered an immunogenic tumor. RCC cells can thus present antigens that are recognized by the host’s immune system, potentially eliciting an anti-tumor immune response. However, RCC tumors have evolved sophisticated strategies to evade or suppress this immune attack.[22]

A primary mechanism of immune escape in ccRCC involves the programmed death (PD-1)/PD-ligand 1 (PD-L1) pathway. Tumor cells, as well as immune cells within the tumor microenvironment (TME), often overexpress PD-L1. This PD-L1 binds to the PD-1 receptor found on activated T-cells. This interaction delivers an inhibitory “off-signal” to T cells, effectively putting the brakes on their anti-tumor activity, thereby allowing cancer cells to escape destruction by the very immune cells designed to eliminate them.[23]

Furthermore, chronic exposure to tumor antigens and continuous inhibitory signaling can lead to T-cell exhaustion, a state characterized by impaired effector function, reduced cytokine production, and increased expression of multiple inhibitory receptors. The RCC TME is also frequently infiltrated by various immunosuppressive cells, such as regulatory T cells and myeloid-derived suppressor cells. These cells actively secrete immunosuppressive cytokines and directly suppress the activity of effector T cells, further dampening the overall anti-tumor immune response and fostering an environment conducive to tumor growth.[23]

THERAPEUTIC ADVANCES

The profound molecular understanding of RCC has dramatically transformed its treatment landscape, shifting from a reliance on non-specific cytotoxic agents to a sophisticated arsenal of highly targeted small molecules and immunomodulatory drugs.

Tyrosine kinase inhibitors (TKIs)

The first wave of targeted therapies for RCC was TKIs. These agents primarily function by blocking the activity of specific RTKs that are constitutively active or overexpressed in RCC, particularly those involved in angiogenesis. Most TKIs target VEGFRs (VEGFR-1, 2, and 3), thereby inhibiting the formation of new blood vessels that are critical for tumor sustenance and growth. Many also inhibit other kinases such as PDGF-R, c-KIT, and RET, contributing to their broader anti-tumor effects.[24]

Key examples of TKIs widely used in RCC include sunitinib, pazopanib, axitinib, cabozantinib, and lenvatinib. These agents have significantly improved progression-free survival (PFS) and overall survival (OS) in patients with advanced RCC compared to prior cytokine-based therapies.[10,17] However, despite their efficacy, resistance to TKIs is common and can develop through various mechanisms, including the activation of alternative pro-angiogenic pathways or the development of compensatory signaling loops. Common side effects associated with TKIs include hypertension, fatigue, hand-foot syndrome, diarrhea, and proteinuria.[24]

mTOR inhibitors

Another class of targeted agents is the mTOR inhibitors, which specifically target the mTORC1 complex. By inhibiting mTORC1, these drugs disrupt critical cellular processes such as protein synthesis, cell growth, and proliferation, ultimately limiting tumor expansion.[25]

Temsirolimus and everolimus are the two primary mTOR inhibitors approved for RCC. Temsirolimus, in particular, has shown benefit in patients with poor-risk metastatic RCC, while everolimus is often utilized in patients whose disease has progressed on prior VEGFR-TKI therapy, or in specific combinations. Common side effects include stomatitis (mouth sores), rash, fatigue, hyperglycemia, and pneumonitis. While their efficacy can be modest in comparison to TKIs in some settings, they remain valuable options in selected patient populations or specific nonccRCC subtypes where mTOR pathway dysregulation is more prominent.[25]

ICIs

The revolutionary advent of ICIs has transformed the treatment paradigm for RCC by harnessing the patient’s own immune system.[16] These agents work by blocking inhibitory pathways that cancer cells exploit to evade immune detection and destruction.

PD-1/PD-L1 inhibitors, such as nivolumab, pembrolizumab, and avelumab, act by preventing the binding of PD-1 on T-cells to PD-L1 expressed on tumor cells or antigen-presenting cells. This effectively “releases the brakes” on anti-tumor T-cell activity, allowing the immune system to recognize and attack cancer cells more effectively. These drugs have demonstrated the capacity to achieve durable responses, including complete remissions, in a subset of ccRCC patients.[26]

Another class of ICIs targets cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). Ipilimumab is the key example in RCC.[17] CTLA-4 acts earlier in the immune response, primarily by inhibiting T-cell priming and activation in the lymph nodes. By blocking CTLA-4, ipilimumab promotes the initial activation and proliferation of T-cells. While both PD-1/PD-L1 and CTLA-4 inhibitors boost anti-tumor immunity, their mechanisms are distinct, leading to synergistic effects when combined. A key consideration for ICIs is the potential for immune-related adverse events, which can affect various organs (e.g., colitis, pneumonitis, thyroiditis, hepatitis) due to generalized immune activation, necessitating careful monitoring and management.[26]

Combination therapies: The new standard

The therapeutic landscape for ccRCC is being further refined by new data from clinical trials. As an ongoing prospective real-world evidence study evaluating belzutifan, a first-in-class HIF-2α inhibitor, for its effectiveness and tolerability across a wide RCC population that goes beyond conventional controlled trial enrollment criteria, the BELIEVE trial is a significant advancement. This includes patients who have undergone extensive pretreatment and have advanced on VEGF-TKIs and/or immune checkpoint inhibitors (ICIs), as well as RCC linked to VHL and sporadic metastatic tumours. Belzutifan may successfully overcome resistance that develops following TKI or ICI treatment by selectively blocking transcriptional programs driven by hypoxia, a key characteristic of RCC. It is anticipated that the trial results will influence the best sequencing tactics, possible combinations, and long-term safety of HIF-2α blockade in standard clinical practice.[26]

Similarly, the COSMIC-313 (NCT03937219) Phase III study is a landmark trial exploring the therapeutic value of triplet checkpoint-targeted therapy, combining cabozantinib (multi-target TKI), nivolumab (PD-1 inhibitor), and ipilimumab (CTLA-4 inhibitor). This strategy addresses multiple distinct oncogenic processes concurrently.

  • Anti-angiogenesis via VEGFR/MET/AXL inhibition (cabozantinib)

  • T-cell activation and persistence via PD-1 blockade (nivolumab), and

  • Priming of naïve T-cells and expansion of tumor-infiltrating lymphocytes via CTLA-4 inhibition (ipilimumab).

Interim analyses have demonstrated notable improvements in PFS compared with the conventional doublet nivolumab + ipilimumab regimen, specifically benefiting intermediate and poor-risk IMDC groups, where rapid disease progression is common. While immunerelated adverse events may increase with intensified therapy, early management protocols have helped maintain a manageable safety profile.

Collectively, BELIEVE and COSMIC-313 signify a paradigm shift toward biomarker-guided, mechanism-integrated therapeutic approaches in advanced ccRCC. Their results are anticipated to shape future first-line treatment algorithms and personalized sequencing, particularly for patients suffering from aggressive disease or those who relapse following current standards of care.[26]

RESISTANCE AND EMERGING TARGETS

Despite the remarkable progress in RCC treatment, a significant challenge remains: the development of resistance to currently available therapies. This resistance can be primary (intrinsic, meaning the tumor is resistant from the outset) or acquired (developing after an initial period of response). Mechanisms are complex and multifaceted, including intratumoral heterogeneity, where different subclones within the same tumor develop distinct resistance pathways.[6,12,16] Hypoxia-driven epithelial-to-mesenchymal transition, activation of parallel pro-angiogenic or pro-survival pathways (e.g., FGF, HGF/MET, PI3K/AKT/mTOR feedback loops), and adaptive metabolic reprogramming all contribute to sustaining tumor growth in the face of targeted therapy or immunotherapy.[8] The quest for reliable predictive biomarkers (e.g., PD-L1 expression, tumor mutational burden, HIF-2α levels) remains under intensive investigation, but they are not yet clinically robust enough to consistently guide treatment selection.[27]

A significant breakthrough in targeting VHL-deficient ccRCC specifically has been the advent of HIF-2α inhibitors, most notably belzutifan (MK-6482).[1,21] Unlike TKIs that indirectly target the consequences of HIF activation (like VEGF), belzutifan directly inhibits the HIF-2α transcription factor itself, preventing it from binding to DNA and upregulating its oncogenic target genes. This highly specific mechanism addresses the fundamental molecular driver in the vast majority of ccRCCs. Belzutifan received accelerated FDA approval in 2021 for VHL-associated ccRCC and, more recently in 2023, received full approval for sporadic ccRCC following prior immune checkpoint and VEGF TKI therapy.[26,27]

The pivotal LITESPARK-005 phase III trial has been instrumental in establishing belzutifan’s role, demonstrating an improved PFS versus everolimus in patients with previously treated advanced ccRCC, although OS benefit is still under evaluation.[9] A recent meta-analysis encompassing 715 patients treated with belzutifan reported a pooled objective response rate of 34%, a disease control rate of 79%, and a median PFS of 8.8 months. The most common Grade ≥3 adverse event was anemia, highlighting a manageable safety profile; encouragingly, efficacy appeared to increase when belzutifan was used in combination with TKIs.[5,15] This agent represents a new pillar in the treatment armamentarium for VHL-mutated ccRCC.[26,27]

FUTURE DIRECTIONS AND FURTHER RESEARCH

1. Antibody–drug conjugates (ADCs) and hypoxic tumors

ADCs are “guided missiles” that carry a strong chemotherapy payload directly to cancer cells using an antibody that recognizes a tumour marker. They are attractive for RCC because some kidney tumours exhibit unique surface markers and areas of low oxygen (hypoxia), which can alter how drugs work. So far, no ADC is approved for RCC, and early trials have been mixed — but newer ADC designs, smarter targets, and combinations with agents that reshape the tumour microenvironment may make ADCs useful in hypoxic RCC in future trials. ADC research in RCC is active and promising, but still early.[27]

2. CAR-T and other engineered T-cell therapies

CAR-T therapy (genetically reprogrammed T cells that attack tumour markers) is transforming blood cancer care and is now being tried in kidney cancer. Trials targeting markers such as CD70 (and combinations of targets) are underway, and regulators have already given advanced designations to some RCC CAR-T projects—showing strong interest. Early data suggest that CAR-T can work in some heavily pretreated patients, but managing severe immune-related side effects and identifying the best target(s) remain key challenges. Longer follow-up and larger studies are needed to show who benefits most.[28]

3. Metabolic inhibitors (glutaminase inhibitors — example: telag lenastat)

Some kidney cancers depend on altered metabolic pathways (for example, glutamine use). Drugs that block glutaminase (the enzyme that helps tumors use glutamine), like telaglenastat, were tested in combination with standard drugs. Early randomized trials gave mixed results — some combinations did not improve outcomes, while other ongoing studies are still exploring new pairings or biomarkers to identify patients who might benefit. The metabolic route still looks promising, but it needs better patient selection and smarter combination strategies.[28]

4. Circulating biomarkers and liquid biopsies (ctDNA, CTCs, cfDNA)

Blood-based tests that measure tumour DNA or circulating tumour cells can track disease without repeated scans or biopsies. In RCC, these tests are improving: they can sometimes predict relapse earlier than imaging and help monitor response to treatment. The technology isn’t yet perfect for every patient (sensitivity varies), but integrating ctDNA and similar markers into routine follow-up could make care more personalized and faster to adapt. Ongoing studies are validating the best assays and how to act on the results.[28]

5. Artificial intelligence (AI) for stratification and decision support

AI tools — from radiology “radiomics” to digital pathology — can spot patterns that humans miss (for example, predict grade, subtype, or likely behaviour from images). These tools are advancing rapidly and already show strong accuracy in classifying tumours and estimating aggressiveness in study settings. The next step is to integrate AI predictions with clinical and molecular data to guide treatment choices, predict who will respond to a drug, and support decisions like surveillance vs surgery. Real-world testing, regulatory approval, and clear clinical workflows are required before routine use.[29,30]

6. How recent meeting data fit in (ASCO GU 2025 and ESMO 2024/2025)

  • ASCO GU 2025 and meeting summaries reported important trial updates that point toward two broad directions: (a) intensifying and improving immunotherapy combinations (for example, triplets that build on PD-1/CTLA-4 combinations), and (b) real-world evidence for new agents like HIF-2α inhibitors (belzutifan). These results support testing new combinations and expanding access to promising drugs while carefully tracking safety.

  • ESMO guidance and congress material from 2024–2025 emphasized personalized approaches, the potential role of HIF-2α blockade, and continued development of biomarkers and novel agents. ESMO also highlighted the need to integrate trial results into practical guidelines for different risk groups.[31,32]

CONCLUSION

The journey of RCC management has been one of remarkable progress, transitioning from a disease often deemed chemo-refractory to one highly amenable to precision-targeted and immunological therapies. Central to this profound transformation is the deep understanding of the VHL–HIF– VEGF axis, which now can be directly drugged through specific HIF-2α inhibitors like belzutifan, representing a truly personalized approach for VHL-deficient tumors. Furthermore, the strategic application of combination therapies, particularly those pairing TKIs with ICIs, has provided synergistic efficacy, offering unprecedented response rates and durable remissions for many patients with advanced disease.

However, the inherent heterogeneity of RCC, the persistent challenge of overcoming treatment resistance, and the need to develop more tailored approaches for non-ccRCC subtypes underscore the ongoing necessity for rigorous translational and clinical research. Future endeavors will likely focus on refining biomarker identification to guide treatment selection more precisely, dissecting the complex mechanisms of resistance, exploring novel metabolic targets, and optimizing increasingly sophisticated combination strategies to overcome current limitations. By continuing to unravel the intricate molecular landscape of RCC, the scientific and medical communities aspire to move ever closer to a future where highly effective, individualized therapies can significantly extend and profoundly improve the quality of life for all patients who have this challenging cancer.

Author contributions:

ARV: Conceptualization, methodology, investigation, writing—original draft preparation, supervision, project administration; MD: Data curation, formal analysis, visualization, validation; DK: Writing—review and editing, resources, supervision.

Ethical approval

Institutional Review Board approval is not required.

Declaration of patient consent

Patient’s consent is not required as there are no patients in this study.

Conflicts of interest

There are no conflicts of interest.

Use of artificial intelligence (AI)-assisted technology for manuscript preparation

The authors confirm that there was no use of artificial intelligence (AI)-assisted technology for assisting in the writing or editing of the manuscript and no images were manipulated using AI.

Financial support and sponsorship: Nil.

References

  1. , , , , , , et al. Phase I dose-escalation trial of PT2385, a first-in-class HIF-2α antagonist in previously treated advanced clear cell renal cell carcinoma. J Clin Oncol. 2018;36:867-74.
    [CrossRef] [PubMed] [Google Scholar]
  2. , , , , , , et al. Review and prospect of immune checkpoint blockade therapy represented by PD-1/PD-L1 in the treatment of clear cell renal cell carcinoma. Oncol Res. 2023;31:255-70.
    [CrossRef] [PubMed] [Google Scholar]
  3. , , , , , , et al. Renal cancer: signaling pathways and advances in targeted therapies. MedComm (2020). 2024;5:e676.
    [CrossRef] [PubMed] [Google Scholar]
  4. , , , , , , et al. The molecular code of kidney cancer: A path of discovery for gene mutation and precision therapy. Mol Aspects Med. 2025;101:101335.
    [CrossRef] [PubMed] [Google Scholar]
  5. , , , , , , et al. Belzutifan versus everolimus for advanced renal-cell carcinoma. N Engl J Med. 2024;391:710-21.
    [CrossRef] [PubMed] [Google Scholar]
  6. , , , . Molecular mechanisms of renal cell carcinoma metastasis and potential targets for therapy. Front Cell Dev Biol. 2025;13:1521151.
    [CrossRef] [PubMed] [Google Scholar]
  7. , , , , . Targeting HIF-2a: The role of belzutifan in clear cell renal carcinoma management. Expert Rev Clin Pharmacol. 2025;18:17-27.
    [CrossRef] [PubMed] [Google Scholar]
  8. , , , , . CCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/HIF-1alpha/VEGF signaling. Neoplasia. 2006;8:394-401.
    [CrossRef] [PubMed] [Google Scholar]
  9. , , , . mTORC1 inhibitors: Is temsirolimus in renal cancer telling us how they really workα. Br J Cancer. 2008;99:1197-203.
    [CrossRef] [PubMed] [Google Scholar]
  10. . Belzutifan Approved for VHL-Associated and Sporadic RCC; First-in-Class HIF-2a Inhibitor. . Available from: https://en.wikipedia.org/wiki/belzutifan [Last accessed 2025 Nov 24]
    [Google Scholar]
  11. , , , , , , et al. Renal cancer: signaling pathways and advances in targeted therapies. MedComm (2020). 2024;5:e676.
    [CrossRef] [PubMed] [Google Scholar]
  12. , , , . mTORC1 inhibitors: Is temsirolimus in renal cancer telling us how they really workα. Br J Cancer. 2008;99:1197-203.
    [CrossRef] [PubMed] [Google Scholar]
  13. Belzutifan Approved for VHL-Associated and Sporadic RCC; First-in-Class HIF-2a Inhibitor. . Wikipedia Regulatory Updates. Available from https://en.wikipedia.org/wiki/belzutifan [Last access 2026 Jun 25]
    [Google Scholar]
  14. , . Molecular landscape of clear cell renal cell carcinoma: Targeting the Wnt/ß-catenin signaling pathway. Discov Oncol. 2025;16:524.
    [CrossRef] [PubMed] [Google Scholar]
  15. , , , , . Targeting HIF-2a: The role of belzutifan in clear cell renal carcinoma management. Expert Rev Clin Pharmacol. 2025;18:17-27.
    [CrossRef] [PubMed] [Google Scholar]
  16. , , , , , , et al. PI3K/AKT/mTOR signalling pathway involvement in renal cell carcinoma pathogenesis (review) Exp Ther Med. 2021;21:540.
    [CrossRef] [PubMed] [Google Scholar]
  17. , , , , , , et al. Systemic treatment of metastatic clear cell renal cell carcinoma in 2018: Current paradigms, use of immunotherapy, and future directions. Eur Urol. 2019;75:100-10.
    [CrossRef] [PubMed] [Google Scholar]
  18. , . Renal cell carcinoma: Review of etiology, pathophysiology and risk factors. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2016;16:183-94.
    [CrossRef] [PubMed] [Google Scholar]
  19. , , , , , , et al. Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors. J Immunother Cancer. 2021;9:e001945.
    [CrossRef] [PubMed] [Google Scholar]
  20. , , , , , , et al. Belzutifan for renal cell carcinoma in von Hippel-Lindau disease. N Engl J Med. 2021;385:2036-46.
    [CrossRef] [PubMed] [Google Scholar]
  21. , . Long non-coding RNAs: Tools for understanding and targeting cancer pathways. Cancers (Basel). 2022;14:4760.
    [CrossRef] [PubMed] [Google Scholar]
  22. , , , , , , et al. CD70-targeted allogeneic CAR T-cell therapy for advanced clear cell renal cell carcinoma. Cancer Discov. 2024;14:1176-89.
    [CrossRef] [PubMed] [Google Scholar]
  23. , , , , , , et al. Liquid biopsy at the frontier in renal cell carcinoma: Recent analysis of techniques and clinical application. Mol Cancer. 2023;22:37.
    [CrossRef] [PubMed] [Google Scholar]
  24. , , , , , et al. Cabozantinib plus telaglenastat in advanced renal cell carcinoma (CANTATA): Randomized phase II trial. JAMA Oncol. 2022;8:1411-8.
    [CrossRef] [PubMed] [Google Scholar]
  25. , , , , , , et al. Inhibition of hypoxiainducible factor-2a in renal cell carcinoma with belzutifan. N Engl J Med. 2021;385:2036-46.
    [Google Scholar]
  26. , , , , , , et al. Circulating tumor DNA and outcomes in metastatic renal cell carcinoma patients treated with immune checkpoint inhibitors. Clin Cancer Res. 2022;28:2117-26.
    [CrossRef] [PubMed] [Google Scholar]
  27. , , , , , , et al. Liquid biopsy in renal cell carcinoma: Applications in precision medicine. Eur Urol Oncol. 2023;6:188-98.
    [Google Scholar]
  28. , , , . Liquid biopsy for renal cell carcinoma: A comprehensive review of techniques, applications, and future prospects. Ther Adv Urol. 2024;8:205-25.
    [CrossRef] [PubMed] [Google Scholar]
  29. , , , , , , et al. Artificial intelligence in renal cell carcinoma histopathology: Current applications and future perspectives. Diagnostics (Basel). 2023;13:2294.
    [CrossRef] [PubMed] [Google Scholar]
  30. , , , , , , et al. Cabozantinib plus nivolumab and ipilimumab in previously untreated, advanced renal cell carcinoma: final results and biomarker analyses from the phase III COSMIC-313 study. Ann Oncol. 2026;37(6):861-871.
    [CrossRef] [PubMed] [Google Scholar]
  31. , , , , , , et al. Belzutifan for von Hippel-Lindau disease-associated renal cell carcinoma. N Engl J Med. 2021;385:2036-46.
    [CrossRef] [PubMed] [Google Scholar]
  32. , , , , , . Diagnostic liquid biopsy biomarkers in renal cell cancer. Nat Rev Urol. 2024;21:133-57.
    [CrossRef] [PubMed] [Google Scholar]
Show Sections